25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BINV (Bioinvent) Stock Analysis
Buy, Hold or Sell?

Let's analyze Bioinvent together

I guess you are interested in BioInvent International AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Bioinvent’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Bioinvent’s Price Targets

I'm going to help you getting a better view of BioInvent International AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BioInvent International AB

I send you an email if I find something interesting about BioInvent International AB.

1. Quick Overview

1.1. Quick analysis of Bioinvent (30 sec.)










1.2. What can you expect buying and holding a share of Bioinvent? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr11.68
Expected worth in 1 year
kr4.63
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
kr-7.05
Return On Investment
-19.4%

For what price can you sell your share?

Current Price per Share
kr36.30
Expected price per share
kr29.00 - kr41.95
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Bioinvent (5 min.)




Live pricePrice per Share (EOD)
kr36.30
Intrinsic Value Per Share
kr-60.30 - kr-49.19
Total Value Per Share
kr-48.61 - kr-37.51

2.2. Growth of Bioinvent (5 min.)




Is Bioinvent growing?

Current yearPrevious yearGrowGrow %
How rich?$80.5m$141.9m-$43.6m-44.4%

How much money is Bioinvent making?

Current yearPrevious yearGrowGrow %
Making money-$12.2m-$8.7m-$3.4m-28.5%
Net Profit Margin-1,203.8%-721.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Bioinvent (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#363 / 872

Most Revenue
#429 / 872

Most Profit
#564 / 872

Most Efficient
#707 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Bioinvent?

Welcome investor! Bioinvent's management wants to use your money to grow the business. In return you get a share of Bioinvent.

First you should know what it really means to hold a share of Bioinvent. And how you can make/lose money.

Speculation

The Price per Share of Bioinvent is kr36.30. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bioinvent.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bioinvent, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr11.68. Based on the TTM, the Book Value Change Per Share is kr-1.76 per quarter. Based on the YOY, the Book Value Change Per Share is kr-1.26 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bioinvent.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.19-0.5%-0.19-0.5%-0.13-0.4%-0.11-0.3%-0.10-0.3%-0.07-0.2%
Usd Book Value Change Per Share-0.19-0.5%-0.18-0.5%-0.13-0.4%-0.07-0.2%0.050.1%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.19-0.5%-0.18-0.5%-0.13-0.4%-0.07-0.2%0.050.1%0.030.1%
Usd Price Per Share3.22-4.06-1.85-3.32-3.46-1.84-
Price to Earnings Ratio-4.35--5.61--3.50--4.80--4.44--0.33-
Price-to-Total Gains Ratio-17.30--22.71--14.17--15.74--16.79-3.36-
Price to Book Ratio2.64-2.73-0.86-1.73-1.81-1.72-
Price-to-Total Gains Ratio-17.30--22.71--14.17--15.74--16.79-3.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.80061
Number of shares263
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.180.05
Usd Total Gains Per Share-0.180.05
Gains per Quarter (263 shares)-48.5413.23
Gains per Year (263 shares)-194.1452.91
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-194-20405343
20-388-398010696
30-582-5920159149
40-777-7860212202
50-971-9800265255
60-1165-11740317308
70-1359-13680370361
80-1553-15620423414
90-1747-17560476467
100-1941-19500529520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%3.037.00.07.5%8.059.018.09.4%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%13.027.00.032.5%25.060.00.029.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.085.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%13.027.00.032.5%25.060.00.029.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BioInvent International AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.780-1.763-1%-1.258-29%-0.672-62%0.480-471%0.280-735%
Book Value Per Share--11.68114.266-18%20.610-43%19.631-40%18.447-37%10.320+13%
Current Ratio--9.41111.226-16%14.713-36%14.332-34%16.137-42%10.388-9%
Debt To Asset Ratio--0.1080.094+15%0.066+63%0.071+51%0.074+46%0.156-31%
Debt To Equity Ratio--0.1210.104+17%0.071+70%0.077+57%0.082+47%0.211-43%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--2678669578.0003362736179.500-20%2163286998.000+24%3010797849.167-11%3101970180.740-14%1669683920.850+60%
Eps---1.770-1.778+0%-1.271-28%-1.078-39%-0.943-47%-0.671-62%
Ev To Ebitda Ratio---5.692-7.091+25%-6.264+10%-6.965+22%-7.306+28%-11.244+98%
Ev To Sales Ratio--30.35783.569-64%46.440-35%55.352-45%84.196-64%47.770-36%
Free Cash Flow Per Share---1.863-1.690-9%-1.296-30%-1.063-43%-0.923-50%-0.664-64%
Free Cash Flow To Equity Per Share---1.897-1.723-9%-1.326-30%-0.699-63%0.465-508%0.490-487%
Gross Profit Margin--1.0001.009-1%1.027-3%1.012-1%1.007-1%1.0040%
Intrinsic Value_10Y_max---49.187----------
Intrinsic Value_10Y_min---60.295----------
Intrinsic Value_1Y_max---2.989----------
Intrinsic Value_1Y_min---4.584----------
Intrinsic Value_3Y_max---10.459----------
Intrinsic Value_3Y_min---15.118----------
Intrinsic Value_5Y_max---19.712----------
Intrinsic Value_5Y_min---27.044----------
Market Cap2388699720.000+15%2029528578.0002553076429.500-21%1162763748.000+75%2084199932.500-3%2173893880.740-7%1158292070.850+75%
Net Profit Margin---5.287-12.038+128%-7.215+36%-7.292+38%-7.823+48%-6.186+17%
Operating Margin---5.566-13.004+134%-7.963+43%-7.991+44%-8.238+48%-6.406+15%
Operating Ratio--6.56613.747-52%8.929-26%8.896-26%9.183-28%7.390-11%
Pb Ratio3.108+15%2.6372.729-3%0.861+206%1.733+52%1.808+46%1.719+53%
Pe Ratio-5.127-18%-4.350-5.609+29%-3.505-19%-4.804+10%-4.441+2%-0.328-92%
Price Per Share36.300+15%30.80038.788-21%17.670+74%31.669-3%33.034-7%17.601+75%
Price To Free Cash Flow Ratio-4.871-18%-4.133-5.880+42%-3.528-15%-4.771+15%-4.448+8%-2.353-43%
Price To Total Gains Ratio-20.393-18%-17.303-22.711+31%-14.167-18%-15.742-9%-16.790-3%3.361-615%
Quick Ratio--12.38915.315-19%22.412-45%20.460-39%20.080-38%12.379+0%
Return On Assets---0.135-0.114-15%-0.058-57%-0.058-57%-0.055-59%-0.110-18%
Return On Equity---0.152-0.126-17%-0.062-59%-0.064-58%-0.061-60%-0.144-5%
Total Gains Per Share---1.780-1.763-1%-1.258-29%-0.672-62%0.480-471%0.280-735%
Usd Book Value--80590416.90098317252.425-18%141998380.350-43%135261170.925-40%127098156.900-37%71103366.675+13%
Usd Book Value Change Per Share---0.186-0.185-1%-0.132-29%-0.070-62%0.050-471%0.029-735%
Usd Book Value Per Share--1.2231.494-18%2.158-43%2.055-40%1.931-37%1.080+13%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--280456704.817352078477.994-20%226496148.691+24%315230534.808-11%324776277.923-14%174815906.513+60%
Usd Eps---0.185-0.186+0%-0.133-28%-0.113-39%-0.099-47%-0.070-62%
Usd Free Cash Flow---12853600.200-11650073.700-9%-8929103.925-31%-7322700.550-43%-6359933.445-51%-4575102.075-64%
Usd Free Cash Flow Per Share---0.195-0.177-9%-0.136-30%-0.111-43%-0.097-50%-0.070-64%
Usd Free Cash Flow To Equity Per Share---0.199-0.180-9%-0.139-30%-0.073-63%0.049-508%0.051-487%
Usd Market Cap250096860.684+15%212491642.117267307102.169-21%121741364.416+75%218215732.933-3%227606689.313-7%121273179.818+75%
Usd Price Per Share3.801+15%3.2254.061-21%1.850+74%3.316-3%3.459-7%1.843+75%
Usd Profit---12211370.400-12251496.675+0%-8756427.450-28%-7324759.650-40%-6433066.395-47%-4594586.745-62%
Usd Revenue--2309682.0001591544.700+45%1600679.775+44%3905955.650-41%3216253.125-28%2342623.238-1%
Usd Total Gains Per Share---0.186-0.185-1%-0.132-29%-0.070-62%0.050-471%0.029-735%
 EOD+5 -3MRQTTM+11 -27YOY+12 -263Y+5 -335Y+5 -3310Y+17 -21

3.3 Fundamental Score

Let's check the fundamental score of BioInvent International AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.127
Price to Book Ratio (EOD)Between0-13.108
Net Profit Margin (MRQ)Greater than0-5.287
Operating Margin (MRQ)Greater than0-5.566
Quick Ratio (MRQ)Greater than112.389
Current Ratio (MRQ)Greater than19.411
Debt to Asset Ratio (MRQ)Less than10.108
Debt to Equity Ratio (MRQ)Less than10.121
Return on Equity (MRQ)Greater than0.15-0.152
Return on Assets (MRQ)Greater than0.05-0.135
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of BioInvent International AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.894
Ma 20Greater thanMa 5035.965
Ma 50Greater thanMa 10034.846
Ma 100Greater thanMa 20031.204
OpenGreater thanClose37.550
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About BioInvent International AB

BioInvent International AB (publ), a clinical-stage company, discovers, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.

Fundamental data was last updated by Penke on 2025-06-27 08:55:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Bioinvent earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compareΒ Bioinvent to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -528.7%Β means thatΒ kr-5.29 for each kr1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioInvent International AB:

  • The MRQ is -528.7%. The company is making a huge loss. -2
  • The TTM is -1,203.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-528.7%TTM-1,203.8%+675.1%
TTM-1,203.8%YOY-721.5%-482.3%
TTM-1,203.8%5Y-782.3%-421.5%
5Y-782.3%10Y-618.6%-163.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-528.7%-93.6%-435.1%
TTM-1,203.8%-140.9%-1,062.9%
YOY-721.5%-197.6%-523.9%
3Y-729.2%-248.5%-480.7%
5Y-782.3%-343.4%-438.9%
10Y-618.6%-496.2%-122.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Bioinvent is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Bioinvent to theΒ Biotechnology industry mean.
  • -13.5% Return on Assets means thatΒ Bioinvent generatedΒ kr-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioInvent International AB:

  • The MRQ is -13.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.5%TTM-11.4%-2.1%
TTM-11.4%YOY-5.8%-5.7%
TTM-11.4%5Y-5.5%-5.9%
5Y-5.5%10Y-11.0%+5.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.5%-11.6%-1.9%
TTM-11.4%-11.6%+0.2%
YOY-5.8%-11.4%+5.6%
3Y-5.8%-11.8%+6.0%
5Y-5.5%-12.0%+6.5%
10Y-11.0%-13.7%+2.7%
4.3.1.3. Return on Equity

Shows how efficient Bioinvent is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Bioinvent to theΒ Biotechnology industry mean.
  • -15.2% Return on Equity means Bioinvent generated kr-0.15Β for eachΒ kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioInvent International AB:

  • The MRQ is -15.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.2%TTM-12.6%-2.5%
TTM-12.6%YOY-6.2%-6.4%
TTM-12.6%5Y-6.1%-6.5%
5Y-6.1%10Y-14.4%+8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.2%-13.5%-1.7%
TTM-12.6%-14.9%+2.3%
YOY-6.2%-14.6%+8.4%
3Y-6.4%-16.8%+10.4%
5Y-6.1%-17.5%+11.4%
10Y-14.4%-19.9%+5.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BioInvent International AB.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Bioinvent is operatingΒ .

  • Measures how much profit Bioinvent makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Bioinvent to theΒ Biotechnology industry mean.
  • An Operating Margin of -556.6%Β means the company generated kr-5.57 Β for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioInvent International AB:

  • The MRQ is -556.6%. The company is operating very inefficient. -2
  • The TTM is -1,300.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-556.6%TTM-1,300.4%+743.8%
TTM-1,300.4%YOY-796.3%-504.2%
TTM-1,300.4%5Y-823.8%-476.7%
5Y-823.8%10Y-640.6%-183.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-556.6%-232.5%-324.1%
TTM-1,300.4%-250.5%-1,049.9%
YOY-796.3%-209.2%-587.1%
3Y-799.1%-234.1%-565.0%
5Y-823.8%-346.1%-477.7%
10Y-640.6%-477.5%-163.1%
4.3.2.2. Operating Ratio

Measures how efficient Bioinvent is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 6.57 means that the operating costs are kr6.57 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of BioInvent International AB:

  • The MRQ is 6.566. The company is inefficient in keeping operating costs low. -1
  • The TTM is 13.747. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ6.566TTM13.747-7.181
TTM13.747YOY8.929+4.819
TTM13.7475Y9.183+4.564
5Y9.18310Y7.390+1.793
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5662.111+4.455
TTM13.7472.694+11.053
YOY8.9293.096+5.833
3Y8.8963.652+5.244
5Y9.1834.745+4.438
10Y7.3906.614+0.776
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BioInvent International AB.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Bioinvent is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 9.41Β means the company has kr9.41 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of BioInvent International AB:

  • The MRQ is 9.411. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.226. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.411TTM11.226-1.816
TTM11.226YOY14.713-3.486
TTM11.2265Y16.137-4.910
5Y16.13710Y10.388+5.748
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.4113.661+5.750
TTM11.2263.846+7.380
YOY14.7134.140+10.573
3Y14.3324.688+9.644
5Y16.1375.746+10.391
10Y10.3886.147+4.241
4.4.3.2. Quick Ratio

Measures if Bioinvent is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Bioinvent to theΒ Biotechnology industry mean.
  • A Quick Ratio of 12.39Β means the company can pay off kr12.39 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioInvent International AB:

  • The MRQ is 12.389. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.315. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.389TTM15.315-2.926
TTM15.315YOY22.412-7.097
TTM15.3155Y20.080-4.765
5Y20.08010Y12.379+7.702
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.3892.848+9.541
TTM15.3153.169+12.146
YOY22.4123.786+18.626
3Y20.4604.311+16.149
5Y20.0805.703+14.377
10Y12.3796.368+6.011
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BioInvent International AB.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of BioinventΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Bioinvent to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11Β means that Bioinvent assets areΒ financed with 10.8% credit (debt) and the remaining percentage (100% - 10.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of BioInvent International AB:

  • The MRQ is 0.108. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.094. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.108TTM0.094+0.014
TTM0.094YOY0.066+0.027
TTM0.0945Y0.074+0.020
5Y0.07410Y0.156-0.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1080.329-0.221
TTM0.0940.349-0.255
YOY0.0660.331-0.265
3Y0.0710.340-0.269
5Y0.0740.349-0.275
10Y0.1560.379-0.223
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Bioinvent is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Bioinvent to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 12.1% means that company has kr0.12 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioInvent International AB:

  • The MRQ is 0.121. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.104. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.121TTM0.104+0.017
TTM0.104YOY0.071+0.032
TTM0.1045Y0.082+0.021
5Y0.08210Y0.211-0.128
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1210.379-0.258
TTM0.1040.437-0.333
YOY0.0710.414-0.343
3Y0.0770.450-0.373
5Y0.0820.464-0.382
10Y0.2110.515-0.304
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every kr1 in earnings Bioinvent generates.

  • Above 15 is considered overpriced butΒ always compareΒ Bioinvent to theΒ Biotechnology industry mean.
  • A PE ratio of -4.35 means the investor is paying kr-4.35Β for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioInvent International AB:

  • The EOD is -5.127. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.350. Based on the earnings, the company is expensive. -2
  • The TTM is -5.609. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.127MRQ-4.350-0.777
MRQ-4.350TTM-5.609+1.259
TTM-5.609YOY-3.505-2.105
TTM-5.6095Y-4.441-1.169
5Y-4.44110Y-0.328-4.113
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.127-2.356-2.771
MRQ-4.350-2.077-2.273
TTM-5.609-2.574-3.035
YOY-3.505-3.760+0.255
3Y-4.804-3.773-1.031
5Y-4.441-6.193+1.752
10Y-0.328-6.876+6.548
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioInvent International AB:

  • The EOD is -4.871. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.133. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.880. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.871MRQ-4.133-0.738
MRQ-4.133TTM-5.880+1.747
TTM-5.880YOY-3.528-2.352
TTM-5.8805Y-4.448-1.432
5Y-4.44810Y-2.353-2.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.871-3.246-1.625
MRQ-4.133-2.705-1.428
TTM-5.880-3.704-2.176
YOY-3.528-4.402+0.874
3Y-4.771-5.070+0.299
5Y-4.448-8.477+4.029
10Y-2.353-9.305+6.952
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Bioinvent is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.64 means the investor is paying kr2.64Β for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of BioInvent International AB:

  • The EOD is 3.108. Based on the equity, the company is fair priced.
  • The MRQ is 2.637. Based on the equity, the company is underpriced. +1
  • The TTM is 2.729. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.108MRQ2.637+0.471
MRQ2.637TTM2.729-0.092
TTM2.729YOY0.861+1.868
TTM2.7295Y1.808+0.921
5Y1.80810Y1.719+0.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.1082.038+1.070
MRQ2.6371.843+0.794
TTM2.7292.125+0.604
YOY0.8612.442-1.581
3Y1.7332.492-0.759
5Y1.8083.652-1.844
10Y1.7194.311-2.592
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets862,794
Total Liabilities93,067
Total Stockholder Equity769,727
 As reported
Total Liabilities 93,067
Total Stockholder Equity+ 769,727
Total Assets = 862,794

Assets

Total Assets862,794
Total Current Assets819,140
Long-term Assets43,654
Total Current Assets
Cash And Cash Equivalents 475,270
Short-term Investments 266,938
Net Receivables 69,233
Inventory 7,699
Total Current Assets  (as reported)819,140
Total Current Assets  (calculated)819,140
+/-0
Long-term Assets
Property Plant Equipment 43,654
Long-term Assets  (as reported)43,654
Long-term Assets  (calculated)43,654
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities87,045
Long-term Liabilities6,022
Total Stockholder Equity769,727
Total Current Liabilities
Short-term Debt 9,164
Other Current Liabilities 77,881
Total Current Liabilities  (as reported)87,045
Total Current Liabilities  (calculated)87,045
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,022
Long-term Liabilities  (as reported)6,022
Long-term Liabilities  (calculated)6,022
+/-0
Total Stockholder Equity
Other Stockholders Equity 769,727
Total Stockholder Equity (as reported)769,727
Total Stockholder Equity (calculated)769,727
+/-0
Other
Cash and Short Term Investments 742,208
Common Stock Shares Outstanding 65,894
Liabilities and Stockholders Equity 862,794
Net Debt -460,084
Net Working Capital 732,095
Property Plant and Equipment Gross 43,654
Short Long Term Debt Total 15,186



6.2. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-06-302002-12-312002-06-302001-12-312001-06-30
> Total Assets 
471,666
410,551
473,622
435,537
393,781
343,185
324,132
287,941
265,574
238,405
212,042
180,182
137,504
266,344
227,558
203,104
168,639
148,332
235,574
193,965
293,852
271,001
219,840
370,870
354,777
295,427
260,375
206,458
158,485
126,246
221,371
215,649
182,938
138,030
190,563
280,629
240,164
205,757
161,835
212,895
180,780
116,543
89,400
57,733
55,636
81,437
54,239
119,254
100,837
74,108
49,352
91,339
69,193
54,447
58,088
243,005
217,295
276,298
238,375
220,194
193,930
170,047
227,213
184,572
144,797
120,400
141,222
316,632
273,798
226,111
194,337
250,820
703,539
802,640
1,626,515
1,588,200
1,520,183
1,447,311
1,380,744
1,556,741
1,755,102
1,712,214
1,656,454
1,598,734
1,483,043
1,400,180
1,328,628
1,198,994
1,087,473
989,236
862,794
862,794989,2361,087,4731,198,9941,328,6281,400,1801,483,0431,598,7341,656,4541,712,2141,755,1021,556,7411,380,7441,447,3111,520,1831,588,2001,626,515802,640703,539250,820194,337226,111273,798316,632141,222120,400144,797184,572227,213170,047193,930220,194238,375276,298217,295243,00558,08854,44769,19391,33949,35274,108100,837119,25454,23981,43755,63657,73389,400116,543180,780212,895161,835205,757240,164280,629190,563138,030182,938215,649221,371126,246158,485206,458260,375295,427354,777370,870219,840271,001293,852193,965235,574148,332168,639203,104227,558266,344137,504180,182212,042238,405265,574287,941324,132343,185393,781435,537473,622410,551471,666
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
107,255
204,053
199,982
168,521
123,783
174,888
265,857
226,913
192,900
150,348
202,722
171,981
109,767
83,346
52,356
50,984
77,509
50,813
107,330
89,170
67,307
42,948
89,623
67,779
53,124
55,848
240,577
212,052
270,650
229,502
209,274
179,998
150,801
208,339
165,151
126,085
102,367
102,730
279,696
239,179
193,106
163,143
220,250
674,346
773,044
1,598,363
1,538,141
1,279,729
1,116,019
1,058,222
1,273,231
1,269,550
1,084,062
1,077,275
1,186,396
1,228,900
1,133,265
1,123,338
1,119,970
1,010,985
943,214
819,140
819,140943,2141,010,9851,119,9701,123,3381,133,2651,228,9001,186,3961,077,2751,084,0621,269,5501,273,2311,058,2221,116,0191,279,7291,538,1411,598,363773,044674,346220,250163,143193,106239,179279,696102,730102,367126,085165,151208,339150,801179,998209,274229,502270,650212,052240,57755,84853,12467,77989,62342,94867,30789,170107,33050,81377,50950,98452,35683,346109,767171,981202,722150,348192,900226,913265,857174,888123,783168,521199,982204,053107,25500000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74,036
29,310
19,774
33,059
36,952
27,779
15,533
18,953
92,343
101,556
93,696
96,622
100,061
77,124
39,764
39,942
64,745
41,776
74,297
70,394
45,627
25,747
62,708
50,534
39,973
41,442
224,459
196,418
226,114
216,031
192,774
162,551
103,700
78,054
144,703
107,097
68,851
28,458
210,343
183,901
153,975
117,127
182,284
642,098
729,270
1,577,077
1,509,661
1,256,516
910,755
769,793
591,224
696,315
515,047
542,516
570,567
589,795
259,548
469,142
470,255
717,362
434,826
475,270
475,270434,826717,362470,255469,142259,548589,795570,567542,516515,047696,315591,224769,793910,7551,256,5161,509,6611,577,077729,270642,098182,284117,127153,975183,901210,34328,45868,851107,097144,70378,054103,700162,551192,774216,031226,114196,418224,45941,44239,97350,53462,70825,74745,62770,39474,29741,77664,74539,94239,76477,124100,06196,62293,696101,55692,34318,95315,53327,77936,95233,05919,77429,31074,03600000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,984
149,804
118,900
110,825
69,118
40,040
238,203
197,664
81,622
36,486
92,552
55,915
0
0
0
0
50,073
30,029
70,054
50,040
37,029
10,009
0
0
0
0
0
0
0
0
0
0
30,060
30,098
30,098
30,135
0
0
0
0
0
0
0
0
0
0
0
6,000
172,074
236,948
386,813
527,049
502,434
475,956
530,599
563,952
809,151
594,962
591,249
232,752
432,333
266,938
266,938432,333232,752591,249594,962809,151563,952530,599475,956502,434527,049386,813236,948172,0746,0000000000000030,13530,09830,09830,060000000000010,00937,02950,04070,05430,02950,073000055,91592,55236,48681,622197,664238,20340,04069,118110,825118,900149,8049,98400000000000000000000000000000
       Net Receivables 
13,562
22,385
26,585
15,120
15,229
5,943
20,856
13,862
16,505
12,566
17,656
13,772
14,842
23,740
21,111
25,124
15,831
15,317
26,300
17,785
29,449
21,998
32,608
215,654
68,254
46,494
39,698
30,088
20,458
15,304
23,782
58,360
22,665
12,116
106,174
11,699
9,968
12,363
12,054
16,257
19,227
71
6,099
12,468
10,774
6,603
8,860
32,954
18,671
4,434
17,115
23,693
14,334
2,273
12,218
16,040
14,352
32,056
13,246
14,215
12,821
1,404
97,852
17,745
16,880
30,566
71,436
63,521
44,485
33,751
40,202
32,393
28,042
29,920
14,395
16,027
10,084
16,342
37,996
283,020
34,948
36,577
44,686
74,476
61,838
32,660
50,258
47,951
50,980
31,247
69,233
69,23331,24750,98047,95150,25832,66061,83874,47644,68636,57734,948283,02037,99616,34210,08416,02714,39529,92028,04232,39340,20233,75144,48563,52171,43630,56616,88017,74597,8521,40412,82114,21513,24632,05614,35216,04012,2182,27314,33423,69317,1154,43418,67132,9548,8606,60310,77412,4686,0997119,22716,25712,05412,3639,96811,699106,17412,11622,66558,36023,78215,30420,45830,08839,69846,49468,254215,65432,60821,99829,44917,78526,30015,31715,83125,12421,11123,74014,84213,77217,65612,56616,50513,86220,8565,94315,22915,12026,58522,38513,562
       Other Current Assets 
0
7,432
0
10,464
0
4,963
0
0
0
7,175
0
0
0
2,749
0
0
0
2,097
0
0
0
1,613
0
0
0
5,358
0
0
0
21,682
23,782
58,360
22,665
17,030
106,174
11,699
9,968
18,653
12,054
16,257
19,227
9,457
6,099
12,468
10,774
5,956
8,860
32,954
18,671
17,185
17,115
23,693
14,334
10,414
12,218
16,040
14,352
10,562
13,246
14,215
12,821
13,251
97,852
17,745
16,880
21,685
71,436
63,521
44,485
21,043
40,202
32,393
28,042
9,775
14,395
16,027
10,084
15,972
37,996
283,020
34,948
42,688
0
0
0
40,792
0
0
0
65,088
0
065,08800040,79200042,68834,948283,02037,99615,97210,08416,02714,3959,77528,04232,39340,20221,04344,48563,52171,43621,68516,88017,74597,85213,25112,82114,21513,24610,56214,35216,04012,21810,41414,33423,69317,11517,18518,67132,9548,8605,95610,77412,4686,0999,45719,22716,25712,05418,6539,96811,699106,17417,03022,66558,36023,78221,6820005,3580001,6130002,0970002,7490007,1750004,963010,46407,4320
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,991
17,318
15,667
14,417
14,247
15,675
14,772
13,251
12,857
11,487
10,173
8,799
6,776
6,054
5,377
4,652
3,928
3,426
11,924
11,667
6,801
6,404
1,716
1,414
1,323
2,240
2,428
5,243
5,648
8,873
10,920
13,932
19,246
18,874
19,421
18,712
18,033
38,492
36,936
34,619
33,005
31,194
30,570
29,193
29,596
28,152
50,059
240,454
331,292
322,522
283,510
485,552
628,152
579,179
412,338
254,143
266,915
205,290
79,024
76,488
46,022
43,654
43,65446,02276,48879,024205,290266,915254,143412,338579,179628,152485,552283,510322,522331,292240,45450,05928,15229,59629,19330,57031,19433,00534,61936,93638,49218,03318,71219,42118,87419,24613,93210,9208,8735,6485,2432,4282,2401,3231,4141,7166,4046,80111,66711,9243,4263,9284,6525,3776,0546,7768,79910,17311,48712,85713,25114,77215,67514,24714,41715,66717,31818,99100000000000000000000000000000
       Property Plant Equipment 
34,608
40,508
40,810
43,816
39,307
34,548
31,517
28,525
25,463
22,440
19,715
17,004
16,526
11,392
13,829
15,219
17,638
13,444
15,246
14,528
13,310
12,281
14,567
15,451
16,217
16,427
15,041
14,199
13,217
11,969
11,569
11,192
10,653
10,445
12,923
12,320
11,099
11,005
9,935
8,921
7,847
6,776
6,054
5,377
4,652
3,928
3,426
2,924
2,667
2,301
1,904
1,716
1,414
1,323
2,240
2,428
5,243
5,648
8,873
10,920
13,932
19,246
18,187
19,421
18,712
18,033
38,492
36,936
34,619
33,005
31,194
30,570
29,193
29,596
28,152
50,059
51,652
49,084
48,402
46,971
44,580
52,012
51,274
51,853
50,367
52,663
50,237
50,278
47,423
45,463
43,654
43,65445,46347,42350,27850,23752,66350,36751,85351,27452,01244,58046,97148,40249,08451,65250,05928,15229,59629,19330,57031,19433,00534,61936,93638,49218,03318,71219,42118,18719,24613,93210,9208,8735,6485,2432,4282,2401,3231,4141,7161,9042,3012,6672,9243,4263,9284,6525,3776,0546,7767,8478,9219,93511,00511,09912,32012,92310,44510,65311,19211,56911,96913,21714,19915,04116,42716,21715,45114,56712,28113,31014,52815,24613,44417,63815,21913,82911,39216,52617,00419,71522,44025,46328,52531,51734,54839,30743,81640,81040,50834,608
       Intangible Assets 
0
0
9,050
19,726
16,981
19,357
22,749
20,522
18,294
16,066
13,839
22,852
20,834
26,489
24,559
22,665
20,771
18,877
16,983
15,396
13,964
12,532
11,100
9,668
13,989
12,384
10,843
9,570
8,296
7,022
5,749
4,475
3,764
3,052
2,752
2,452
2,152
1,852
1,552
1,252
952
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000009521,2521,5521,8522,1522,4522,7523,0523,7644,4755,7497,0228,2969,57010,84312,38413,9899,66811,10012,53213,96415,39616,98318,87720,77122,66524,55926,48920,83422,85213,83916,06618,29420,52222,74919,35716,98119,7269,05000
       Other Assets 
0
0
9,050
19,726
16,981
19,357
22,749
20,522
18,294
16,066
13,839
22,852
20,834
30,183
24,559
22,665
20,771
21,674
16,983
15,396
13,964
14,433
11,100
9,668
13,989
12,384
10,843
9,570
8,296
7,022
5,749
4,475
3,764
3,052
2,752
2,452
2,152
1,852
1,552
1,252
952
0
0
0
0
0
0
9,000
9,000
4,500
4,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,828
13,890
16,779
16,762
16,905
17,726
20,928
0
22,494
22,589
21,723
0
26,557
28,962
29,303
0
0
0
0
0
0
00000029,30328,96226,557021,72322,58922,494020,92817,72616,90516,76216,77913,89015,82800000000000000000004,5004,5009,0009,0000000009521,2521,5521,8522,1522,4522,7523,0523,7644,4755,7497,0228,2969,57010,84312,38413,9899,66811,10014,43313,96415,39616,98321,67420,77122,66524,55930,18320,83422,85213,83916,06618,29420,52222,74919,35716,98119,7269,05000
> Total Liabilities 
62,244
22,135
57,128
41,287
43,594
38,228
39,067
27,445
28,981
25,727
25,343
45,803
33,132
47,344
38,725
46,241
33,453
38,180
52,624
43,205
41,623
56,883
45,706
62,894
78,699
64,129
63,584
62,955
57,306
70,613
58,756
75,115
67,013
63,839
56,606
49,001
43,618
67,805
60,203
106,526
111,727
68,919
56,033
33,778
27,105
32,430
24,128
28,091
19,946
21,680
18,662
18,243
18,695
24,993
28,346
30,313
33,112
45,861
30,299
35,597
30,539
39,822
41,552
42,030
24,446
32,779
51,382
69,315
63,343
56,675
57,881
57,402
49,739
59,141
61,292
80,082
74,688
80,324
81,457
89,367
70,843
106,092
92,609
122,405
76,774
90,453
95,991
101,478
84,380
103,421
93,067
93,067103,42184,380101,47895,99190,45376,774122,40592,609106,09270,84389,36781,45780,32474,68880,08261,29259,14149,73957,40257,88156,67563,34369,31551,38232,77924,44642,03041,55239,82230,53935,59730,29945,86133,11230,31328,34624,99318,69518,24318,66221,68019,94628,09124,12832,43027,10533,77856,03368,919111,727106,52660,20367,80543,61849,00156,60663,83967,01375,11558,75670,61357,30662,95563,58464,12978,69962,89445,70656,88341,62343,20552,62438,18033,45346,24138,72547,34433,13245,80325,34325,72728,98127,44539,06738,22843,59441,28757,12822,13562,244
   > Total Current Liabilities 
62,244
22,135
57,128
41,287
43,594
38,228
39,067
27,445
28,981
25,727
25,343
45,803
33,132
47,344
38,725
46,241
33,453
38,180
52,624
43,205
41,623
56,883
45,706
62,894
78,699
64,129
63,584
62,955
57,306
70,613
58,756
75,115
67,013
63,839
56,606
49,001
43,618
67,805
60,203
106,526
111,727
68,919
56,033
33,778
27,105
32,430
24,128
28,091
19,946
21,680
18,662
18,243
18,695
24,993
28,346
30,313
33,112
45,861
30,299
35,597
30,539
39,822
41,552
42,030
24,446
32,779
37,639
56,987
52,438
47,203
49,851
50,823
44,620
53,509
57,307
54,947
51,684
58,792
61,407
70,808
53,785
87,319
75,745
107,239
63,316
75,918
83,516
91,076
76,065
95,206
87,045
87,04595,20676,06591,07683,51675,91863,316107,23975,74587,31953,78570,80861,40758,79251,68454,94757,30753,50944,62050,82349,85147,20352,43856,98737,63932,77924,44642,03041,55239,82230,53935,59730,29945,86133,11230,31328,34624,99318,69518,24318,66221,68019,94628,09124,12832,43027,10533,77856,03368,919111,727106,52660,20367,80543,61849,00156,60663,83967,01375,11558,75670,61357,30662,95563,58464,12978,69962,89445,70656,88341,62343,20552,62438,18033,45346,24138,72547,34433,13245,80325,34325,72728,98127,44539,06738,22843,59441,28757,12822,13562,244
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,057
6,057
6,057
-37,977
6,057
6,057
6,057
-47,260
6,183
6,183
6,939
-48,603
6,731
6,626
6,521
8,190
8,190
7,966
7,741
8,709
8,709
8,709
8,709
9,198
9,164
9,1649,1988,7098,7098,7098,7097,7417,9668,1908,1906,5216,6266,731-48,6036,9396,1836,183-47,2606,0576,0576,057-37,9776,0576,0576,057000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,057
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000006,057000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
6,933
0
12,861
0
6,057
0
0
0
8,582
0
0
0
14,795
0
0
0
12,772
0
0
0
14,115
0
0
0
12,784
0
0
0
16,510
0
0
0
17,282
0
0
0
19,457
0
0
0
13,349
0
0
0
9,446
0
0
0
7,588
0
0
0
9,647
0
0
0
10,291
0
0
0
14,171
0
0
0
10,821
0
0
0
14,361
0
0
0
16,913
51,124
48,764
44,745
19,720
54,676
64,182
47,264
41,346
67,555
99,273
55,575
29,189
74,807
82,367
67,356
49,095
0
049,09567,35682,36774,80729,18955,57599,27367,55541,34647,26464,18254,67619,72044,74548,76451,12416,91300014,36100010,82100014,17100010,2910009,6470007,5880009,44600013,34900019,45700017,28200016,51000012,78400014,11500012,77200014,7950008,5820006,057012,86106,9330
       Other Current Liabilities 
0
15,202
0
28,426
0
32,171
0
0
0
17,145
25,343
45,803
33,132
32,549
38,725
46,241
33,453
25,408
52,624
43,205
41,623
42,768
45,706
62,894
78,699
51,345
63,584
62,955
57,306
54,103
58,756
75,115
67,013
46,557
56,606
49,001
43,618
48,348
60,203
106,526
111,727
55,570
56,033
33,778
27,105
22,984
24,128
28,091
19,946
14,092
18,662
18,243
18,695
15,346
28,346
30,313
33,112
35,570
30,299
35,597
30,539
25,651
41,552
42,030
24,446
21,958
31,582
50,930
46,381
9,536
43,794
44,766
38,563
8,016
51,124
48,764
44,745
9,036
54,676
64,182
47,264
37,783
67,555
99,273
55,575
38,020
74,807
82,367
67,356
86,008
77,881
77,88186,00867,35682,36774,80738,02055,57599,27367,55537,78347,26464,18254,6769,03644,74548,76451,1248,01638,56344,76643,7949,53646,38150,93031,58221,95824,44642,03041,55225,65130,53935,59730,29935,57033,11230,31328,34615,34618,69518,24318,66214,09219,94628,09124,12822,98427,10533,77856,03355,570111,727106,52660,20348,34843,61849,00156,60646,55767,01375,11558,75654,10357,30662,95563,58451,34578,69962,89445,70642,76841,62343,20552,62425,40833,45346,24138,72532,54933,13245,80325,34317,14500032,171028,426015,2020
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,743
12,328
10,905
9,472
8,030
6,579
5,119
5,632
3,985
25,135
23,004
21,532
20,050
18,559
17,058
18,773
16,864
15,166
13,458
14,535
12,475
10,402
8,315
8,215
6,022
6,0228,2158,31510,40212,47514,53513,45815,16616,86418,77317,05818,55920,05021,53223,00425,1353,9855,6325,1196,5798,0309,47210,90512,32813,743000000000000000000000000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,119
5,632
3,985
25,135
23,004
21,532
20,050
18,559
17,058
18,773
16,864
15,166
13,458
0
0
0
0
0
0
00000013,45815,16616,86418,77317,05818,55920,05021,53223,00425,1353,9855,6325,119000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
409,422
388,416
416,494
394,250
350,187
304,957
285,065
260,496
236,593
212,678
186,699
134,379
104,372
219,000
188,833
156,863
135,186
110,152
182,950
150,760
252,229
214,118
174,134
307,976
276,078
231,298
196,791
143,503
101,179
55,633
162,615
140,534
115,925
74,191
133,957
231,628
196,546
137,952
101,632
106,369
69,053
47,624
33,367
23,955
28,531
49,007
30,111
91,163
80,891
52,428
30,690
73,096
50,498
29,454
29,742
212,692
184,183
230,437
208,076
184,597
163,391
130,225
185,661
142,542
120,351
87,621
89,840
247,317
210,455
169,436
136,456
193,418
653,800
743,499
1,565,223
1,508,118
1,445,495
1,366,987
1,299,287
1,467,374
1,684,259
1,606,122
1,563,845
1,476,329
1,406,269
1,309,727
1,232,637
1,097,516
1,003,093
885,815
769,727
769,727885,8151,003,0931,097,5161,232,6371,309,7271,406,2691,476,3291,563,8451,606,1221,684,2591,467,3741,299,2871,366,9871,445,4951,508,1181,565,223743,499653,800193,418136,456169,436210,455247,31789,84087,621120,351142,542185,661130,225163,391184,597208,076230,437184,183212,69229,74229,45450,49873,09630,69052,42880,89191,16330,11149,00728,53123,95533,36747,62469,053106,369101,632137,952196,546231,628133,95774,191115,925140,534162,61555,633101,179143,503196,791231,298276,078307,976174,134214,118252,229150,760182,950110,152135,186156,863188,833219,000104,372134,379186,699212,678236,593260,496285,065304,957350,187394,250416,494388,416409,422
   Common Stock
0
14,072
0
14,738
0
14,738
0
0
0
14,738
14,738
14,738
14,738
23,580
188,833
156,863
135,186
23,580
182,950
150,760
252,229
27,830
174,134
307,976
276,078
27,830
196,791
143,503
101,179
27,830
30,500
140,534
115,925
30,548
133,957
231,628
196,546
33,603
101,632
106,369
69,053
36,963
33,367
23,955
28,531
6,801
30,111
91,163
80,891
9,023
30,690
73,096
50,498
13,033
29,742
212,692
184,183
24,376
208,076
184,597
163,391
24,376
185,623
142,542
120,351
28,064
89,840
247,317
210,455
40,142
136,456
193,418
653,800
78,752
11,700
11,700
11,700
11,694
11,700
11,700
13,000
12,994
13,200
13,200
13,200
13,161
13,200
13,200
13,200
0
0
0013,20013,20013,20013,16113,20013,20013,20012,99413,00011,70011,70011,69411,70011,70011,70078,752653,800193,418136,45640,142210,455247,31789,84028,064120,351142,542185,62324,376163,391184,597208,07624,376184,183212,69229,74213,03350,49873,09630,6909,02380,89191,16330,1116,80128,53123,95533,36736,96369,053106,369101,63233,603196,546231,628133,95730,548115,925140,53430,50027,830101,179143,503196,79127,830276,078307,976174,13427,830252,229150,760182,95023,580135,186156,863188,83323,58014,73814,73814,73814,73800014,738014,738014,0720
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
1,287,587
0
0
1
1,550,645
1,463,129
1,393,069
1
1,219,437
1,084,316
0
0
0
0001,084,3161,219,43711,393,0691,463,1291,550,6451001,287,587100010001000100010001000100010001000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
805,146
162,615
140,534
115,925
946,831
133,957
231,628
196,546
1,072,053
0
106,369
69,053
1,165,215
0
23,955
28,531
1,214,749
30,111
91,163
80,891
1,269,851
30,690
73,096
50,498
1,333,432
29,742
212,692
184,183
1,585,601
208,076
184,597
163,391
1,585,601
38
142,542
120,351
1,662,245
89,840
247,317
210,455
1,870,236
136,456
193,418
653,800
2,482,063
1,553,523
1,496,418
1,433,795
3,449,915
1,287,587
1,455,674
1,671,259
3,728,464
1,550,645
1,463,129
1,393,069
3,759,256
1,219,437
1,084,316
989,893
885,815
769,727
769,727885,815989,8931,084,3161,219,4373,759,2561,393,0691,463,1291,550,6453,728,4641,671,2591,455,6741,287,5873,449,9151,433,7951,496,4181,553,5232,482,063653,800193,418136,4561,870,236210,455247,31789,8401,662,245120,351142,542381,585,601163,391184,597208,0761,585,601184,183212,69229,7421,333,43250,49873,09630,6901,269,85180,89191,16330,1111,214,74928,53123,95501,165,21569,053106,36901,072,053196,546231,628133,957946,831115,925140,534162,615805,14600000000000000000000000000000



6.3. Balance Sheets

Currency in SEK. All numbers in thousands.




6.4. Cash Flows

Currency in SEK. All numbers in thousands.




6.5. Income Statements

Currency in SEK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue44,686
Cost of Revenue-0
Gross Profit44,68644,686
 
Operating Income (+$)
Gross Profit44,686
Operating Expense-515,745
Operating Income-471,059-471,059
 
Operating Expense (+$)
Research Development457,733
Selling General Administrative58,302
Selling And Marketing Expenses0
Operating Expense515,745516,035
 
Net Interest Income (+$)
Interest Income42,090
Interest Expense-555
Other Finance Cost-0
Net Interest Income41,535
 
Pretax Income (+$)
Operating Income-471,059
Net Interest Income41,535
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-429,240-512,878
EBIT - interestExpense = -429,240
-429,240
-428,820
Interest Expense555
Earnings Before Interest and Taxes (EBIT)-428,685-428,685
Earnings Before Interest and Taxes (EBITDA)-409,385
 
After tax Income (+$)
Income Before Tax-429,240
Tax Provision-135
Net Income From Continuing Ops-429,375-429,375
Net Income-429,375
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses515,745
Total Other Income/Expenses Net41,819-41,535
 

Technical Analysis of Bioinvent
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bioinvent. The general trend of Bioinvent is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bioinvent's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Bioinvent Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioInvent International AB.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 41.45 < 41.90 < 41.95.

The bearish price targets are: 37.25 > 33.50 > 29.00.

Know someone who trades $BINV? Share this with them.πŸ‘‡

BioInvent International AB Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioInvent International AB. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioInvent International AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioInvent International AB. The current macd is 0.39138866.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Bioinvent price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Bioinvent. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Bioinvent price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BioInvent International AB Daily Moving Average Convergence/Divergence (MACD) ChartBioInvent International AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioInvent International AB. The current adx is 16.52.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Bioinvent shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
BioInvent International AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioInvent International AB. The current sar is 39.14.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BioInvent International AB Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioInvent International AB. The current rsi is 52.89. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
BioInvent International AB Daily Relative Strength Index (RSI) ChartBioInvent International AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioInvent International AB. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bioinvent price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
BioInvent International AB Daily Stochastic Oscillator ChartBioInvent International AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioInvent International AB. The current cci is 82.09.

BioInvent International AB Daily Commodity Channel Index (CCI) ChartBioInvent International AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioInvent International AB. The current cmo is 4.36391381.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BioInvent International AB Daily Chande Momentum Oscillator (CMO) ChartBioInvent International AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioInvent International AB. The current willr is -39.13043478.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Bioinvent is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BioInvent International AB Daily Williams %R ChartBioInvent International AB Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of BioInvent International AB.

BioInvent International AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioInvent International AB. The current atr is 1.53807977.

BioInvent International AB Daily Average True Range (ATR) ChartBioInvent International AB Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioInvent International AB. The current obv is 3,481,033.

BioInvent International AB Daily On-Balance Volume (OBV) ChartBioInvent International AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioInvent International AB. The current mfi is 53.08.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
BioInvent International AB Daily Money Flow Index (MFI) ChartBioInvent International AB Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioInvent International AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

BioInvent International AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioInvent International AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.894
Ma 20Greater thanMa 5035.965
Ma 50Greater thanMa 10034.846
Ma 100Greater thanMa 20031.204
OpenGreater thanClose37.550
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Bioinvent with someone you think should read this too:
  • Are you bullish or bearish on Bioinvent? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bioinvent? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioInvent International AB

I send you an email if I find something interesting about BioInvent International AB.


Comments

How you think about this?

Leave a comment

Stay informed about BioInvent International AB.

Receive notifications about BioInvent International AB in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.